These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15613698)

  • 21. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
    Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
    Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy.
    Bolis G; Villa A; Guarnerio P; Ferraris C; Gavoni N; Giardina G; Melpignano M; Scarfone G; Zanaboni F; Parazzini F
    Cancer; 1996 Jan; 77(1):128-31. PubMed ID: 8630918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
    J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
    Bristow RE; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
    J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
    Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
    Leiser AL; Chi DS; Ishill NM; Tew WP
    Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital.
    Linasmita V; Wilailak S; Srisupundit S; Tangtrakul S; Bullangpoti S; Israngura N
    J Med Assoc Thai; 1998 Jan; 81(1):10-6. PubMed ID: 9470316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
    Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR
    Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
    Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.
    Onda T; Yoshikawa H; Yasugi T; Matsumoto K; Taketani Y
    Jpn J Clin Oncol; 2010 Jan; 40(1):36-41. PubMed ID: 19820253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
    Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
    Huang X; Cai SM; Tang J; Li ZT; Zang RY
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):602-5. PubMed ID: 15498187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma.
    Liu EL; Mi RR
    Chin Med J (Engl); 2004 Oct; 117(10):1547-51. PubMed ID: 15498381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.